PROPHASE LABS INC (PRPH) Fundamental Analysis & Valuation

NASDAQ:PRPH • US74345W1080

0.3626 USD
-0.08 (-18.97%)
At close: Jan 2, 2026
0.1814 USD
-0.18 (-49.97%)
After Hours: 1/2/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PRPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

Overall PRPH gets a fundamental rating of 0 out of 10. We evaluated PRPH against 193 industry peers in the Pharmaceuticals industry. PRPH may be in some trouble as it scores bad on both profitability and health. PRPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. PRPH Profitability Analysis

1.1 Basic Checks

  • In the past year PRPH has reported negative net income.
  • In the past year PRPH has reported a negative cash flow from operations.
  • In multiple years PRPH reported negative net income over the last 5 years.
  • PRPH had negative operating cash flow in 4 of the past 5 years.
PRPH Yearly Net Income VS EBIT VS OCF VS FCFPRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -81.22%, PRPH is doing worse than 73.96% of the companies in the same industry.
  • PRPH has a worse Return On Equity (-777.79%) than 82.81% of its industry peers.
Industry RankSector Rank
ROA -81.22%
ROE -777.79%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
PRPH Yearly ROA, ROE, ROICPRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • PRPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRPH Yearly Profit, Operating, Gross MarginsPRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. PRPH Health Analysis

2.1 Basic Checks

  • PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PRPH has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PRPH has more shares outstanding
  • PRPH has a worse debt/assets ratio than last year.
PRPH Yearly Shares OutstandingPRPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
PRPH Yearly Total Debt VS Total AssetsPRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -3.94, we must say that PRPH is in the distress zone and has some risk of bankruptcy.
  • PRPH has a Altman-Z score (-3.94) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.74 indicates that PRPH is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.74, PRPH is not doing good in the industry: 69.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACC15.08%
PRPH Yearly LT Debt VS Equity VS FCFPRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • PRPH has a Current Ratio of 0.14. This is a bad value and indicates that PRPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PRPH's Current ratio of 0.14 is on the low side compared to the rest of the industry. PRPH is outperformed by 95.31% of its industry peers.
  • A Quick Ratio of 0.14 indicates that PRPH may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.14, PRPH is not doing good in the industry: 94.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
PRPH Yearly Current Assets VS Current LiabilitesPRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PRPH Growth Analysis

3.1 Past

  • The earnings per share for PRPH have decreased strongly by -138.78% in the last year.
  • PRPH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.65%.
  • The Revenue has been decreasing by -7.32% on average over the past years.
EPS 1Y (TTM)-138.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.33%
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-71.93%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.56%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRPH Yearly Revenue VS EstimatesPRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PRPH Yearly EPS VS EstimatesPRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. PRPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRPH. In the last year negative earnings were reported.
  • Also next year PRPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRPH Price Earnings VS Forward Price EarningsPRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRPH Per share dataPRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRPH Dividend Analysis

5.1 Amount

  • PRPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRPH Fundamentals: All Metrics, Ratios and Statistics

PROPHASE LABS INC

NASDAQ:PRPH (1/2/2026, 8:00:01 PM)

After market: 0.1814 -0.18 (-49.97%)

0.3626

-0.08 (-18.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17
Earnings (Next)03-30
Inst Owners5.25%
Inst Owner Change-92.07%
Ins Owners5.75%
Ins Owner Change0%
Market Cap15.95M
Revenue(TTM)6.77M
Net Income(TTM)-53.36M
Analysts82.86
Price TargetN/A
Short Float %0.19%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-75.17%
Min Revenue beat(2)-84.79%
Max Revenue beat(2)-65.56%
Revenue beat(4)0
Avg Revenue beat(4)-89.42%
Min Revenue beat(4)-164.6%
Max Revenue beat(4)-42.74%
Revenue beat(8)0
Avg Revenue beat(8)-80.88%
Revenue beat(12)2
Avg Revenue beat(12)-55.26%
Revenue beat(16)6
Avg Revenue beat(16)-28.97%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.36
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-23.4
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.15
BVpS0.16
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.22%
ROE -777.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.84%
Cap/Sales 3.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -3.94
F-Score3
WACC15.08%
ROIC/WACCN/A
Cap/Depr(3y)44.05%
Cap/Depr(5y)127.73%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-138.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.33%
EPS Next Y97.56%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-71.93%
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-82.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.44%
OCF growth 3YN/A
OCF growth 5YN/A

PROPHASE LABS INC / PRPH FAQ

What is the ChartMill fundamental rating of PROPHASE LABS INC (PRPH) stock?

ChartMill assigns a fundamental rating of 0 / 10 to PRPH.


What is the valuation status for PRPH stock?

ChartMill assigns a valuation rating of 0 / 10 to PROPHASE LABS INC (PRPH). This can be considered as Overvalued.


Can you provide the profitability details for PROPHASE LABS INC?

PROPHASE LABS INC (PRPH) has a profitability rating of 0 / 10.


What is the earnings growth outlook for PROPHASE LABS INC?

The Earnings per Share (EPS) of PROPHASE LABS INC (PRPH) is expected to grow by 97.56% in the next year.


How sustainable is the dividend of PROPHASE LABS INC (PRPH) stock?

The dividend rating of PROPHASE LABS INC (PRPH) is 0 / 10 and the dividend payout ratio is 0%.